---
company: RadNet, Inc.
ticker: RDNT
form: 8-K
filed: 2026-11-09
accepted: 2026-11-09T12:50:25+00:00
accession: 0001683168-26-008404
source: https://www.sec.gov/Archives/edgar/data/790526/000168316826008404/
---

# RadNet (RDNT) Q3 2026 earnings

## Header

- Company: RadNet, Inc.
- Reported: 2026-11-09 07:50 BMO ET
- Source: 8-K only — accession 0001683168-26-008404, Item 2.02 + Exhibit 99.1
- Verdict: Record quarterly Revenue and Adjusted EBITDA with expanded margins, driven by advanced imaging mix and Digital Health growth.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---:|---:|---:|---|
| Revenue | $638.3M | +22.1% | +2.6% | Ex. 99.1, income statement |
| EPS (GAAP) | $0.05 | -27.9% | -50.0% | Ex. 99.1, income statement |
| EPS (adjusted) | $0.30 | +25.0% | +3.4% | Ex. 99.1, income statement |
| Net income | $4.2M | -22.2% | -44.0% | Ex. 99.1, income statement |

## Revenue breakdown

| Segment | Actual | YoY | Share of revenue | Note |
|---|---:|---:|---:|---|
| Imaging Center | $605.4M | +21.8% | 94.9% | Adjusted EBITDA margin 16.0% |
| Digital Health | $32.9M | +32.6% | 5.1% | Adjusted EBITDA margin 9.2% |

## Margins and costs

- Gross margin: 16.5% (prior 16.3%, change +0.2 pp)
- Operating expenses: $608.0M (+22.5% YoY)
- One-offs in the quarter: $1.2M severance; $7.5M gain on contribution of imaging centers; $0.6M de novo facility lease expense; $5.4M loss on disposal of equipment; $7.3M intangibles amortization; $5.6M non-capitalized R&D; $2.8M legal settlements; $2.7M acquisition transaction costs; $8.3M non-cash change in contingent consideration; $2.1M lease abandonment charges
- Effective tax rate: 31.6% (prior-year 31.5%, year-to-date 31.0%)
- Non-GAAP bridge: Adds back severance, intangibles amortization, non-capitalized R&D, legal settlements, acquisition costs, contingent consideration, lease abandonment, and non-operational rent

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---|---:|
| Total Company Revenue | $638.3M | $622.7M | $522.9M | +2.6% QoQ, +22.1% YoY |
| Adjusted EBITDA | $105.0M | $99.7M | $84.9M | +5.3% QoQ, +23.8% YoY |
| Digital Health Revenue | $32.9M | $32.4M | $24.8M | +1.5% QoQ, +32.6% YoY |
| ARR | $105.5M | $105.5M | $53.5M | 0.0% QoQ, +97.2% YoY |
| Advanced Imaging Mix | 30.6% | 29.9% | 28.2% | +0.7 pp QoQ, +2.4 pp YoY |
| Cash | $750.6M | $726.3M | N/A | +3.3% QoQ |
| Net Debt to Adjusted EBITDA | 1.66x | 1.63x | N/A | +0.03x QoQ |

## Guidance

| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Imaging Center Revenue | Revised upwards | Revised upwards | Raised after Q2 results |
| Imaging Center Adjusted EBITDA | Revised upwards | Revised upwards | Raised after Q2 results |
| Imaging Center Free Cash Flow | Revised upwards | Revised upwards | Raised after Q2 results |
| Digital Health Adjusted EBITDA | Revised upwards | Revised upwards | Raised after Q2 results |

## What drove it

- Revenue story: Total Company Revenue grew 22.1% YoY (+2.6% QoQ) driven by advanced imaging mix shift, new center openings, and acquisitions; Digital Health Revenue grew 32.6% YoY (+1.5% QoQ).
- EPS story: GAAP EPS declined YoY due to higher expenses and a larger share count; Adjusted EPS grew YoY driven by revenue growth and margin expansion.
- One-off check: Adjusted Earnings of $23.8M vs GAAP Net Income of $4.2M, driven by add-backs totaling $19.6M (severance, intangibles amortization, R&D, settlements, acquisition costs, contingent consideration, lease abandonment, non-operational rent).

## The good

- Record quarterly Revenue and Adjusted EBITDA
- Adjusted EBITDA margin expanded 23 basis points
- Advanced imaging mix increased to 30.6%
- Digital Health ARR grew 97.2% YoY to $105.5M
- Cash balance of $750.6M and Net Debt to AEBITDA of 1.66x

## The bad

- Digital Health Adjusted EBITDA decreased 11.8% YoY due to investments
- GAAP Net Income declined YoY despite revenue growth
- Weighted average shares outstanding increased YoY

## The ugly

- none

## Open questions

- Specifics of the revised 2026 guidance ranges for Revenue, Adjusted EBITDA, and Free Cash Flow
- Specifics of the revised 2026 guidance ranges for Digital Health Adjusted EBITDA

## Full release

### RadNet (RDNT) earnings release, November 9, 2026

RadNet, Inc. (RDNT) · Form 8-K, Item 2.02 · Filed 2026-11-09 · [SEC filing](https://www.sec.gov/Archives/edgar/data/790526/000168316826008404/)

RadNet Reports Third Quarter Financial Results with Record Quarterly

Revenue and Adjusted EBITDA

(1) and Revises Upwards 2026 Financial Guidance Ranges

LOS ANGELES, California, November 8, 2026 – RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services and a premier global developer of digital health solutions, today reported financial results for its third quarter of 2026.

Dr. Howard Berger, President and Chief Executive

Officer of RadNet, commented, “We delivered record quarterly Revenue and Adjusted EBITDA

(1) in the third quarter. Total

Company Revenue grew 22.1% and Adjusted EBITDA

(1) grew 23.8% compared with last year’s third quarter, and Adjusted EBITDA

(1) margin expanded 23 basis points. These results were driven by continued initiatives to create and fill capacity at existing imaging centers, new center openings, the continued shift in the business mix towards advanced imaging, tuck-in acquisitions, improved reimbursement from commercial payors, the expansion of our health system joint ventures and 32.6% Revenue growth in the Digital Health segment.”

Dr. Berger continued, “Advanced imaging growth continues to be strong, both in aggregate and on a same-center basis. Compared with last year’s third quarter, aggregate advanced imaging procedural volumes increased 19.9% and same-center advanced imaging procedural volumes increased 8.9%. As a result, RadNet’s advanced imaging business mix increased 232 basis points, from 28.2% of all procedures in the third quarter of 2025 to 30.6% in the third quarter of 2026.”

“With strong performance across nearly every part of the core imaging center business, we are again raising certain guidance ranges in anticipation that full-year results will exceed both our original expectations and the revised ranges issued in conjunction with first and second quarter 2026 results. We are raising

2026 Imaging Center guidance ranges for Revenue, Adjusted EBITDA

(1) and Free Cash Flow

(2),” added Dr. Berger.

Dr. Berger continued, “We are particularly excited about the opportunities for growth and expansion that will be made possible as a result of the recently announced pending acquisition of ONRAD. The inbound interest from current joint venture partners and potential new partners and customers has exceeded our expectations.

The strategic fit that ONRAD’s capabilities have with both RadNet’s core imaging center business and Digital Health solutions is already being recognized in the imaging marketplace, and we look forward to the opportunities that could result once the acquisition is closed.”

“RadNet’s balance sheet remains healthy and continues to provide the operating flexibility necessary to achieve further growth. We ended the third quarter with $750.6 million in cash and a Net Debt to Adjusted EBITDA

(1) leverage ratio of 1.66x. This liquidity enables us to keep investing in organic growth and to pursue attractive strategic acquisitions in the coming quarters,” concluded Dr. Berger.

Third Quarter Financial Results

For the third quarter of 2026, RadNet reported

Total Company Revenue of $638.3 million and Adjusted EBITDA

(1) of $105.0 million. Revenue increased $115.4 million (or 22.1%) and Adjusted EBITDA

(1) increased $20.2 million (or 23.8%) as compared with the third quarter of 2025.

For the third quarter of 2026, RadNet reported

Digital Health Revenue (inclusive of intersegment revenue) of $32.9 million and Adjusted EBITDA

(1) of $3.0 million. Revenue increased $8.1 million (or 32.6%) and Adjusted EBITDA

(1) decreased $0.4 million (or -11.8%) as compared with the third quarter of 2025.

Unadjusted for unusual or one-time items impacting the third quarter, Total Company Net Income for the third quarter of 2026 was $4.2 million as compared with a Total Company Net Income of $5.4 million for the third quarter of 2025. Fully diluted Net Income Per Share for the third quarter of 2026 was $0.05, compared with a fully diluted Net Income Per Share of $0.07 in the third quarter of 2025, based upon a weighted average number of diluted shares outstanding of 79.2 million shares in the third quarter of 2026 and 77.4 million shares in the third quarter of 2025.

There were a number of unusual, one-time and noteworthy items impacting the third quarter including: $1.2 million in severance expense related to cost-savings initiatives; $7.5 million gain on the contribution of imaging centers into joint ventures; $0.6 million expense related to leases for de novo facilities under construction that have yet to open their operations; $5.4 million loss on the disposal of equipment; $7.3 million intangibles amortization expense related to the Digital Health operating segment; $5.6 million of non-capitalized research and development expenses related to the DeepHealth

Cloud OS and AI solutions; $2.8 million in legal settlements; $2.7 million of acquisition transaction costs; $8.3 million in non-cash change in contingent consideration; and $2.1 million of lease abandonment charges. Adjusting for the above items, Total Company Adjusted

Earnings

(3) was $23.8 million and diluted Adjusted Earnings Per Share

(3) was $0.30 during the third quarter of 2026.

This compares with Total Company Adjusted Earnings

(3) of $18.8 million and diluted Adjusted Earnings Per Share

(3) of $0.24 during the third quarter of 2025.

For the third quarter of 2026, as compared with the prior year’s third quarter, MRI volume increased 18.3%, CT volume increased 22.0% and PET/CT volume increased 30.4%. Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 10.8% over the... (truncated)uarters of 2026 and 2025, MRI volume increased 8.2%, CT volume increased 10.2% and PET/CT volume increased 8.2%. Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 3.2% over the prior year’s same quarter

Nine Month Financial Results

For the first nine months of 2026, RadNet reported

Total Company Revenue of $1,836.6 million and Adjusted EBITDA

(1) of $268.0 million. Revenue increased $344.1 million (or 23.1%) and Adjusted EBITDA

(1) increased $55.4 million (or 26.1%) as compared with the first nine months of 2025.

For the first nine months of 2026, RadNet reported

Digital Health Revenue (inclusive of intersegment revenue) of $94.5 million and Adjusted EBITDA

(1) of $6.8 million. Revenue increased $29.7 million (or 45.8%) and Adjusted EBITDA

(1) decreased $3.7 million (or -35.4%) as compared with the first nine months of 2025.

Unadjusted for one-time or unusual items, Total

Company Net Loss for the first nine months of 2026 was $21.8 million as compared with a Total Company Net Loss of $18.1 million for the first nine months of 2025. Fully diluted Net Loss Per Share for the nine month period of 2026 was $(0.28), compared with a fully diluted

Net Loss Per Share of $(0.24) in the nine month period of 2025, based upon a weighted average number of diluted shares outstanding of

77.6 million shares for the nine month period in 2026 and 74.7 million shares for the nine month period in 2025.

2026 Guidance Update

RadNet amends its previously announced guidance levels as follows:

Imaging Center Segment

Digital Health Segment

Dr. Berger explained, “The Imaging Center segment has outperformed projections in each of the first three quarters of this year. As a result, we are raising its guidance ranges for Revenue, Adjusted EBITDA

(1) and Free Cash Flow

(2). In the Digital Health segment, we are raising the Adjusted

EBITDA

(1) guidance range as a result of effective expense management and faster-than-projected integration of acquired operations.”

Conference Call for Tomorrow

Dr. Howard Berger, President and Chief Executive

Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its third quarter

2026 results on Monday, November 9th, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Conference Call Details:

Date: Monday, November 9, 2026

Time: 10:30 a.m. Eastern Time

Dial In-Number: 844-744-1280

International Dial-In Number: 412-564-6465

It is recommended that participants dial in approximately 5 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1780998&tp_key=f33fc0e8e8 or http://www.radnet.com under the “Investors” menu section and “News Releases” sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10213035.

About RadNet, Inc.

RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.

RadNet has a network of owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California,

Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 12,000 team members. Learn more at www.radnet.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,”

“project,” “estimate,” “expect,” “strategy,” “future,” “likely,”

“may,” “should,” “will” and similar references to future periods. Forward-looking statements in this press release include, among others, statements about our anticipated business results, balance sheet and liquidity and our future liquidity, burn rate and our continuing ability to service or refinance our current indebtedness.

Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

Any forward-looking statement contained in this current report is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation... (truncated)ing statement, whether written or oral, that we may make from time to time, whether as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable law.

Regulation G: GAAP and Non-GAAP Financial

Information

This release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.

CONTACTS:

RadNet, Inc.

Mark Stolper, 310-445-2800

Executive Vice President and Chief Financial

Officer

#### Financial statements

##### Income Statement (Three Months Ended September 30, — (unaudited) (in thousands))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| Service fee revenue | 607,015 | 491,426 | 1,744,822 | 1,398,838 |
| Revenue under capitation arrangements | 31,242 | 31,443 | 91,786 | 93,660 |
| Total service revenue | 638,257 | 522,869 | 1,836,608 | 1,492,498 |
| **OPERATING EXPENSES** | | | | |
| Cost of operations, excluding depreciation and amortization | 552,382 | 450,379 | 1,637,534 | 1,332,944 |
| Lease abandonment charges | 2,052 | 2,819 | 3,358 | 8,330 |
| Depreciation and amortization | 47,010 | 39,799 | 137,506 | 111,275 |
| Loss (gain) on sale and disposal of equipment and other | 5,359 | 1,042 | 9,067 | 3,168 |
| Severance costs | 1,193 | 1,441 | 3,317 | 2,614 |
| Total operating expenses | 607,996 | 495,480 | 1,790,782 | 1,458,331 |
| INCOME (LOSS) FROM OPERATIONS | 30,261 | 27,389 | 45,826 | 34,167 |
| **OTHER INCOME AND EXPENSES** | | | | |
| Interest expense | 20,682 | 17,355 | 56,492 | 51,783 |
| Equity in earnings of joint ventures | -4,200 | -3,567 | -12,735 | -10,522 |
| Non-cash change in fair value of interest rate hedge |  | 2,371 |  | 6,433 |
| Debt restructuring and extinguishment expenses |  |  | 3,368 |  |
| Loss (gain) on contribution of imaging centers into joint venture | -7,528 |  | -7,528 |  |
| Other (income) expenses | -6,205 | -9,044 | -15,072 | -24,520 |
| Total other (income) expenses | 2,749 | 7,115 | 24,525 | 23,174 |
| INCOME (LOSS) BEFORE INCOME TAXES | 27,512 | 20,274 | 21,301 | 10,993 |
| Provision for income taxes | -8,361 | -6,385 | -6,628 | -3,807 |
| NET INCOME (LOSS) | 19,151 | 13,889 | 14,673 | 7,186 |
| Net income (loss) attributable to noncontrolling interests | 14,998 | 8,472 | 36,456 | 25,241 |
| NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | 4,153 | 5,417 | -21,783 | -18,055 |
| BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | 0.05 | 0.07 | -0.28 | -0.24 |
| DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | 0.05 | 0.07 | -0.28 | -0.24 |
| **WEIGHTED AVERAGE SHARES OUTSTANDING** | | | | |
| Basic | 77,926,702 | 75,950,350 | 77,594,151 | 74,703,658 |
| Diluted | 79,174,226 | 77,388,477 | 77,594,151 | 74,703,658 |

##### Income Statement (Three Months Ended September 30, — (IN THOUSANDS))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| Net income (loss) attributable to Radnet, Inc. common stockholders | 4,153 | 5,417 | -21,783 | -18,055 |
| Income taxes | 8,361 | 6,385 | 6,628 | 3,807 |
| Interest expense | 20,682 | 17,355 | 56,492 | 51,783 |
| Severance costs | 1,193 | 1,441 | 3,317 | 2,614 |
| Depreciation and amortization | 47,010 | 39,799 | 137,506 | 111,275 |
| Non-cash employee stock-based compensation | 10,018 | 9,041 | 51,933 | 46,276 |
| Loss (gain) on sale and disposal of equipment and other | 5,359 | 1,042 | 9,067 | 3,168 |
| Non-cash change in fair value of interest rate hedge |  | 2,371 |  | 6,433 |
| Other expenses (income) | -6,205 | -9,044 | -15,072 | -24,520 |
| Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | 5,565 | 5,486 | 15,235 | 13,835 |
| Lease abandonment charges | 2,052 | 2,819 | 3,358 | 8,330 |
| Loss (gain) on contribution of imaging centers into joint venture | -7,528 |  | -7,528 |  |
| Loss (gain) on extinguishment of debt and related expenses |  |  | 3,368 |  |
| Legal settlements | 2,815 |  | 2,815 |  |
| Non-cash change to contingent consideration | 8,257 |  | 7,864 |  |
| Non-operational rent expenses | 604 | 621 | 2,002 | 2,459 |
| Acquisition transaction costs | 2,708 | 2,136 | 12,761 | 5,109 |
| Adjusted EBITDA - Radnet, Inc. | 105,044 | 84,869 | 267,963 | 212,514 |
| **NOTE** | | | | |
| Adjusted EBITDA - Imaging Center Segment | 101,998 | 81,417 | 261,136 | 201,948 |
| Adjusted EBITDA - Digital Health Segment | 3,046 | 3,452 | 6,827 | 10,566 |

##### Balance Sheet (September 30, 2026 — (IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA))

| | September 30, 2026 – (unaudited) | December 31, 2025 |
|---|---:|---:|
| **CURRENT ASSETS** | | |
| Cash and Cash equivalents | 750,607 | 767,215 |
| Accounts receivable | 248,893 | 200,317 |
| Due from affiliates | 5,600 | 12,592 |
| Prepaid expenses and other current assets | 63,341 | 52,003 |
| Total current assets | 1,068,441 | 1,032,127 |
| **PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS** | | |
| Property and equipment, net | 904,274 | 807,702 |
| Operating lease right-of-use assets | 755,606 | 690,250 |
| Total property, equipment and right-of-use assets | 1,659,880 | 1,497,952 |
| **OTHER ASSETS** | | |
| Goodwill | 1,136,986 | 907,663 |
| Other intangible assets | 235,063 | 148,508 |
| Deferred financing costs | 1,248 | 1,684 |
| Investment in joint ventures | 131,507 | 130,340 |
| Deposits and other | 47,273 | 40,289 |
| Total Assets | 4,280,398 | 3,758,563 |
| **CURRENT LIABILITIES** | | |
| Accounts payable, accrued expenses and other | 500,750 | 422,029 |
| Due to affiliates | 96,065 | 70,104 |
| Deferred revenue | 16,116 | 7,272 |
| Current operating lease liability | 70,598 | 61,934 |
| Current portion of notes payable | 31,796 | 25,424 |
| Current portion of finance lease | 1,317 |  |

##### Cash Flow (Original Guidance Range — Digital Health Segment (in millions))

| | Original Guidance Range | Revised Guidance Range After Q1 Results | Revised Guidance Range After Q2 Results | Revised Guidance Range After Q3 Results |
|---|---:|---:|---:|---:|
| Total Net Revenue (inclusive of intersegment revenue) | $135 - $145 million | $135 - $145 million | $135 - $145 million | $135 - $145 million |
| Adjusted EBITDA(1) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | $10 - $12 million | $10 - $12 million | $10 - $12 million | $11 - $13 million |
| Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | $17 - $19 million | $17 - $19 million | $17 - $19 million | $17 - $19 million |
| Capital Expenditures | $9 - $12 million | $9 - $12 million | $9 - $12 million | $10 - $13 million |
| Free Cash Flow(2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | $(1) - $3 million | $(1) - $3 million | $(1) - $3 million | $(1) - $3 million |

##### Cash Flow (Nine Months Ended September 30, — (unaudited) (in thousands))

| | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|
| Net income | 14,673 | 7,186 |
| **Adjustments to reconcile net income to net cash provided by operating activities:** | | |
| Depreciation and amortization | 137,506 | 111,275 |
| Noncash operating lease expense | 49,425 | 44,605 |
| Equity in earnings of joint ventures, net of dividends | -4,244 | -4,590 |
| Amortization of deferred financing costs and loan discount | 2,355 | 2,242 |
| Loss on sale and disposal of equipment | 9,067 | 3,168 |
| Loss on extinguishment of debt | 407 |  |
| Gain on contribution of imaging centers into joint venture | -7,528 |  |
| Lease abandonment charges | 3,358 | 8,330 |
| Amortization of cash flow hedge |  | 2,273 |
| Non-cash change in fair value of interest rate swap |  | 6,433 |
| Stock-based compensation | 51,933 | 46,276 |
| Change in fair value of contingent consideration | 7,864 |  |
| **Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:** | | |
| Accounts receivable | -30,461 | -20,476 |
| Other current assets | -4,292 | 2,093 |
| Other assets | -7,478 | -2,764 |
| Deferred taxes | 4,334 | 2 |
| Operating leases | -45,252 | -48,760 |
| Deferred revenue | 581 | 3,934 |
| Accounts payable, accrued expenses and other | 81,393 | 53,429 |
| Net cash provided by operating activities | 263,641 | 214,656 |
| **CASH FLOWS FROM INVESTING ACTIVITIES** | | |
| Purchase of imaging facilities and other acquisitions, net of cash acquired | -315,708 | -66,464 |
| Purchase of property and equipment and other | -181,721 | -162,221 |
| Proceeds from sale of equipment | 1,270 | 75 |
| Equity contributions in existing and purchase of interest in joint ventures |  | -4,147 |
| Collection of notes receivable | 8,541 | 2,832 |
